Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds

breast cancer

  • Biodistribution of <sup>18</sup>F-FES in Patients with Metastatic ER+ Breast Cancer Undergoing Treatment with Rintodestrant (G1T48), a Novel Selective ER Degrader
    You have access
    Biodistribution of 18F-FES in Patients with Metastatic ER+ Breast Cancer Undergoing Treatment with Rintodestrant (G1T48), a Novel Selective ER Degrader
    Ramsha Iqbal, Maqsood Yaqub, Daniela E. Oprea-Lager, Yeukman Liu, Anne Marije Luik, Andy P. Beelen, Robert C. Schuit, Albert D. Windhorst, Ronald Boellaard and Catharina W. Menke-van der Houven van Oordt
    Journal of Nuclear Medicine May 1, 2022, 63 (5) 694-699; DOI: https://doi.org/10.2967/jnumed.121.262500
  • Imaging Androgen Receptors in Breast Cancer with <sup>18</sup>F-Fluoro-5α-Dihydrotestosterone PET: A Pilot Study
    You have access
    Imaging Androgen Receptors in Breast Cancer with 18F-Fluoro-5α-Dihydrotestosterone PET: A Pilot Study
    Heather Jacene, Mofei Liu, Su-Chun Cheng, Amanda Abbott, Shipra Dubey, Keisha McCall, Diane Young, Mayzie Johnston, Annick D. Van den Abbeele and Beth Overmoyer
    Journal of Nuclear Medicine January 1, 2022, 63 (1) 22-28; DOI: https://doi.org/10.2967/jnumed.121.262068
  • Open Access
    Use of 64Cu-DOTA-Trastuzumab PET to Predict Response and Outcome of Patients Receiving Trastuzumab Emtansine (T-DM1) for Metastatic Breast Cancer: A Pilot Study
    Joanne E. Mortimer, James R. Bading, Paul H Frankel, Mary Caroll, Yuan Yuan, Jinha Park, Lusine Tumyan, Nikita Gidwaney, Erasmus Kofi Poku, John E Shively and David Colcher
    Journal of Nuclear Medicine December 2, 2021, jnumed.121.262940; DOI: https://doi.org/10.2967/jnumed.121.262940
  • Determining the Axillary Nodal Status with 4 Current Imaging Modalities, Including <sup>18</sup>F-FDG PET/MRI, in Newly Diagnosed Breast Cancer: A Comparative Study Using Histopathology as the Reference Standard
    You have access
    Determining the Axillary Nodal Status with 4 Current Imaging Modalities, Including 18F-FDG PET/MRI, in Newly Diagnosed Breast Cancer: A Comparative Study Using Histopathology as the Reference Standard
    Janna Morawitz, Nils-Martin Bruckmann, Frederic Dietzel, Tim Ullrich, Ann-Kathrin Bittner, Oliver Hoffmann, Svjetlana Mohrmann, Lena Häberle, Marc Ingenwerth, Lale Umutlu, Wolfgang Peter Fendler, Tanja Fehm, Ken Herrmann, Gerald Antoch, Lino Morris Sawicki and Julian Kirchner
    Journal of Nuclear Medicine December 1, 2021, 62 (12) 1677-1683; DOI: https://doi.org/10.2967/jnumed.121.262009
  • Value of <sup>18</sup>F-FES PET in Solving Clinical Dilemmas in Breast Cancer Patients: A Retrospective Study
    You have access
    Value of 18F-FES PET in Solving Clinical Dilemmas in Breast Cancer Patients: A Retrospective Study
    Jorianne Boers, Naila Loudini, Celina L. Brunsch, Sylvia A. Koza, Erik F.J. de Vries, Andor W.J.M. Glaudemans, Geke A.P. Hospers and Carolina P. Schröder
    Journal of Nuclear Medicine September 1, 2021, 62 (9) 1214-1220; DOI: https://doi.org/10.2967/jnumed.120.256826
  • Phase I Trial of <sup>131</sup>I-GMIB-Anti-HER2-VHH1, a New Promising Candidate for HER2-Targeted Radionuclide Therapy in Breast Cancer Patients
    You have access
    Phase I Trial of 131I-GMIB-Anti-HER2-VHH1, a New Promising Candidate for HER2-Targeted Radionuclide Therapy in Breast Cancer Patients
    Matthias D’Huyvetter, Jens De Vos, Vicky Caveliers, Ilse Vaneycken, Johannes Heemskerk, Francois P. Duhoux, Christel Fontaine, Marian Vanhoeij, Albert D. Windhorst, Frank van der Aa, N. Harry Hendrikse, Jos L.E. Eersels, Hendrik Everaert, Pieterjan Gykiere, Nick Devoogdt, Geert Raes, Tony Lahoutte and Marleen Keyaerts
    Journal of Nuclear Medicine August 1, 2021, 62 (8) 1097-1105; DOI: https://doi.org/10.2967/jnumed.120.255679
  • Sentinel Lymph Node Biopsy in Breast Cancer with <sup>99m</sup>Tc-Tilmanocept: A Multicenter Study on Real-Life Use of a Novel Tracer
    You have access
    Sentinel Lymph Node Biopsy in Breast Cancer with 99mTc-Tilmanocept: A Multicenter Study on Real-Life Use of a Novel Tracer
    Sergi Vidal-Sicart, María Eugenia Rioja, Andrea Prieto, Elena Goñi, Isabel Gómez, María Dolores Albala, Luis Lumbreras, Luisa Fernanda León, José Ramón Gómez and Francisco Campos
    Journal of Nuclear Medicine May 10, 2021, 62 (5) 620-627; DOI: https://doi.org/10.2967/jnumed.120.252064
  • Head-to-Head Evaluation of <sup>18</sup>F-FES and <sup>18</sup>F-FDG PET/CT in Metastatic Invasive Lobular Breast Cancer
    You have access
    Head-to-Head Evaluation of 18F-FES and 18F-FDG PET/CT in Metastatic Invasive Lobular Breast Cancer
    Gary A. Ulaner, Komal Jhaveri, Sarat Chandarlapaty, Vaios Hatzoglou, Christopher C. Riedl, Jason S. Lewis and Audrey Mauguen
    Journal of Nuclear Medicine March 1, 2021, 62 (3) 326-331; DOI: https://doi.org/10.2967/jnumed.120.247882
  • You have access
    Initial Clinical Results of a Novel Immuno-PET Theranostic Probe in Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer
    Caroline Rousseau, David M. Goldenberg, Mathilde Colombié, Jean-Charles Sébille, Philippe Meingan, Ludovic Ferrer, Pierre Baumgartner, Evelyne Cerato, Damien Masson, Mario Campone, Aurore Rauscher, Vincent Fleury, Catherine Labbe, Alain Faivre Chauvet, Jean-Sebastien Fresnel, Claire Toquet, Jacques Barbet, Robert M. Sharkey, Loic Campion and Françoise Kraeber-Bodéré
    Journal of Nuclear Medicine August 1, 2020, 61 (8) 1205-1211; DOI: https://doi.org/10.2967/jnumed.119.236000
  • You have access
    Initial Studies with 11C-Vorozole PET Detect Overexpression of Intratumoral Aromatase in Breast Cancer
    Anat Biegon, Kenneth R. Shroyer, Dinko Franceschi, Jasbeer Dhawan, Mouna Tahmi, Deborah Pareto, Patrick Bonilla, Krystal Airola and Jules Cohen
    Journal of Nuclear Medicine June 1, 2020, 61 (6) 807-813; DOI: https://doi.org/10.2967/jnumed.119.231589

Pages

  • Next
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
SNMMI

© 2022 Journal of Nuclear Medicine

Powered by HighWire